metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-29 DIFFERENCES IN THE PROGRESSION OF BODY COMPOSITION AND LIVER DAMAGE IN A MU...
Información de la revista
Vol. 29. Núm. S3.
Abstracts of the 2023 Annual Meeting of the ALEH
(diciembre 2024)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 29. Núm. S3.
Abstracts of the 2023 Annual Meeting of the ALEH
(diciembre 2024)
Acceso a texto completo
P-29 DIFFERENCES IN THE PROGRESSION OF BODY COMPOSITION AND LIVER DAMAGE IN A MURINE MODEL OF METABOLIC SYNDROME: A SEX PERSPECTIVE
Visitas
11
Laura Manjarrés1, Aline Xavier2, Leticia González1, Camila Garrido1, Flavia Zacconi3, Carlos Sing-Long1, Marcelo Andia1
1 Biomedical Imaging Center, Radiology Department, School of Medicine. Pontificia Universidad Católica de Chile, Santiago, Chile, Santiago, Chile
2 Biomedical Engineering, School of Engineering, Universidad de Santiago de Chile, Santiago, Chile, Santiago, Chile
3 Faculty of Chemistry and Pharmacy, Pontificia Universidad Católica de Chile, Santiago, Chile, Santiago, Chile
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Descargar PDF
Estadísticas
Figuras (1)
Suplemento especial
Este artículo forma parte de:
Vol. 29. Núm S3

Abstracts of the 2023 Annual Meeting of the ALEH

Más datos
Conflict of interest

No

Introduction and Objectives

The Metabolic dysfunction associated with fatty liver (MAFLD) is the most common hepatic affection worldwide1. The critical pathophysiological hallmark of MAFLD is the hepatocyte's accumulation of intracellular fats2.

The gold standard for diagnosing MAFLD is liver biopsy; however, this method is invasive and cannot be used to follow the progression of the disease. On the other hand, changes in total weight and body fat distribution can be used for clinically suspected indicators of MAFLD progression3,4; however, sex dependence is not completely elucidated.

This study aims to investigate the sex differences in body composition changes and their relationship with liver disease progression in the eNOS KO. The eNOS KO is a metabolic model of MAFLD and recapitulates the disease in 8-12 weeks when fed a high-calorie and high-fat diet5.

Patients / Materials and Methods

We fed 8 groups of 12-week-old eNOS KO mice for 0 weeks (n=6), 4 weeks (n=6), 8 weeks (n=6), and 12 weeks (n=6)

At each time point, an in vivo MRI imaging of body composition and Dixon Quant quantification were acquired using a Philips Ingenia 3T MR scan. We harvested the liver each time for histology analyses and obtained plasma for serological measurements.

All data were analyzed using no parametric statistics in Prism 9.0.0 (GraphPad Software Inc, La Jolla, CA). Principal Component Analysis (PCA) statistical package R v4.0.2.

Results and Discussion

Males and females increased their weight during the diet intervention (23% males, 13% females, fig. 1A); however, both groups ate a similar amount of food. Males showed greater visceral fat accumulation than females throughout the intervention period; when we adjust for body weight, males have a significantly higher proportion of visceral fat volume per unit of mass than females (fig. 1B).

During the dietary intervention, the mice showed a progressive increase in the NAS score, with females reaching a maximum score of 3 and males reaching 5 (fig. 1C).

Using the dimensionality reduction technique and the KNN classification boundary, it was possible to demonstrate that the animals are grouped according to the progression of the disease but also grouped by sex (fig. 1D).

Conclusions

The progression of MAFLD showed different phenotypes in males and females. Using markers from body composition, liver and muscle fat fraction, it was possible to identify sex-dependent clusters that correlate with the liver damage progression. Our results suggest the need to identify diagnostic and progression markers of MAFLD differentiated by sex.

El Texto completo está disponible en PDF
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos